急性缺血性卒中的静脉溶栓治疗：从阿替普酶到替奈普酶。
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase.
作者信息
Yang Nan, Lee Hangil, Wu Chuanjie
机构信息
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA.
出版信息
Brain Circ. 2023 Jun 30;9(2):61-63. doi: 10.4103/bc.bc_70_22. eCollection 2023 Apr-Jun.
Abstract
Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
摘要
中风是全球发病和死亡的主要原因之一。虽然静脉注射阿替普酶进行溶栓已被广泛证明对急性缺血性中风患者有益，但它仍有许多局限性。替奈普酶是阿替普酶的改良版，是一种潜在的静脉溶栓替代药物，比阿替普酶更具优势。这篇小型综述的目的是总结重症缺血性中风静脉溶栓的进展，特别是从阿替普酶到替奈普酶的发展和转变。
相似文献
1
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase.急性缺血性卒中的静脉溶栓治疗：从阿替普酶到替奈普酶。
Brain Circ. 2023 Jun 30;9(2):61-63. doi: 10.4103/bc.bc_70_22. eCollection 2023 Apr-Jun.
2
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?使用替奈普酶治疗急性缺血性脑卒中：为何还未普及？
West J Emerg Med. 2020 Feb 24;21(2):199-202. doi: 10.5811/westjem.2020.1.45279.
3
Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.替奈普酶与阿替普酶用于卒中溶栓评估（TASTE）：一项多中心、前瞻性、随机、开放标签、盲终点、对照 III 期非劣效性试验方案。
Int J Stroke. 2023 Jul;18(6):751-756. doi: 10.1177/17474930231154390. Epub 2023 Feb 2.
4
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.加拿大急性缺血性脑卒中静脉内替奈普酶与阿替普酶比较（AcT）：一项实用的、多中心、开放标签、与登记系统相关联、随机化、对照、非劣效性试验。
Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29.
5
Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety.替奈普酶与阿替普酶用于低收入国家尼泊尔急性缺血性卒中治疗的成本、疗效及安全性
Cureus. 2018 Feb 9;10(2):e2178. doi: 10.7759/cureus.2178.
6
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review.替奈普酶与阿替普酶治疗急性缺血性卒中的系统评价
Int J Emerg Med. 2022 Jan 4;15(1):1. doi: 10.1186/s12245-021-00399-w.
7
Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.替奈普酶静脉溶栓治疗大血管闭塞患者的系统评价和荟萃分析。
Stroke. 2021 Jan;52(1):308-312. doi: 10.1161/STROKEAHA.120.030220. Epub 2020 Dec 4.
8
Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States.在美国现实环境中，静脉注射替奈普酶和静脉注射阿替普酶用于急性缺血性卒中（无论是否进行血栓切除术）的疗效。
J Stroke Cerebrovasc Dis. 2023 Feb;32(2):106898. doi: 10.1016/j.jstrokecerebrovasdis.2022.106898. Epub 2022 Dec 6.
9
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.阿替普酶与替奈普酶治疗缺血性脑卒中溶栓（ATTEST）：一项 2 期、随机、开放标签、盲终点研究。
Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.
10
Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System.在一个卫生系统中实施替奈普酶治疗急性缺血性卒中方案。
Innov Pharm. 2024 Mar 18;15(1). doi: 10.24926/iip.v15i1.5801. eCollection 2024.
引用本文的文献
1
Molecular targets of neuroplasticity in ischemic stroke: insights from GEO database, single-cell analysis and immune infiltration analysis.缺血性中风中神经可塑性的分子靶点：来自GEO数据库、单细胞分析和免疫浸润分析的见解
Front Aging Neurosci. 2025 Jul 25;17:1561282. doi: 10.3389/fnagi.2025.1561282. eCollection 2025.
2
Prediction of outcomes following intravenous thrombolysis in patients with acute ischemic stroke using serum UCH-L1, S100β, and NSE: a multicenter prospective cohort study employing machine learning methods.利用血清泛素羧基末端水解酶L1（UCH-L1）、S100β蛋白和神经元特异性烯醇化酶（NSE）预测急性缺血性脑卒中患者静脉溶栓后的预后：一项采用机器学习方法的多中心前瞻性队列研究
Ther Adv Neurol Disord. 2025 Jun 10;18:17562864251342429. doi: 10.1177/17562864251342429. eCollection 2025.
3
A matters arising: discussion on urokinase dosing and individualized treatment strategies in the TRUST trial.待决事项：TRUST试验中尿激酶剂量及个体化治疗策略的讨论
BMC Med. 2025 May 28;23(1):309. doi: 10.1186/s12916-025-04151-6.
4
Clinical outcomes of endovascular therapy in acute basilar artery occlusion with low pc-ASPECTS : Outcomes in ABAO with low pc-ASPECTS.低灌注脑-急性卒中早期CT评分的急性基底动脉闭塞血管内治疗的临床结局：低灌注脑-急性卒中早期CT评分的急性基底动脉闭塞的结局
J Neurol. 2025 May 13;272(6):395. doi: 10.1007/s00415-025-13144-7.
5
Mitigating Early Phosphatidylserine Exposure in a Tmem30a-Dependent Way Ameliorates Neuronal Damages After Ischemic Stroke.以Tmem30a依赖的方式减轻早期磷脂酰丝氨酸暴露可改善缺血性中风后的神经元损伤。
MedComm (2020). 2025 Mar 18;6(4):e70140. doi: 10.1002/mco2.70140. eCollection 2025 Apr.
6
Endothelial Cells and the Blood-Brain Barrier: Critical Determinants of Ineffective Reperfusion in Stroke.内皮细胞与血脑屏障：卒中再灌注无效的关键决定因素
Eur J Neurosci. 2025 Feb;61(3):e16663. doi: 10.1111/ejn.16663.
7
Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.血管内再灌注治疗大血管闭塞急性缺血性卒中后动脉内注射替奈普酶：POST-TNK随机临床试验
JAMA. 2025 Feb 18;333(7):579-588. doi: 10.1001/jama.2024.23466.
8
Exosomes in Central Nervous System Diseases: A Comprehensive Review of Emerging Research and Clinical Frontiers.中枢神经系统疾病中的外泌体：新兴研究与临床前沿的综合综述
Biomolecules. 2024 Nov 27;14(12):1519. doi: 10.3390/biom14121519.
9
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial.辅助性前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂依洛尤单抗预防非心源性急性缺血性卒中早期神经功能恶化的多中心、前瞻性、随机、开放标签临床试验
CNS Drugs. 2025 Feb;39(2):197-208. doi: 10.1007/s40263-024-01145-5. Epub 2025 Jan 5.
10
Electroacupuncture Protects Against Cerebral Ischemia-Reperfusion Injury: Reducing Inflammatory Response and Cell Pyroptosis by Inhibiting P2X7/NLRP3/GSDMD Pathway.电针预防脑缺血再灌注损伤：通过抑制P2X7/NLRP3/GSDMD通路减轻炎症反应和细胞焦亡
Neuropsychiatr Dis Treat. 2024 Nov 27;20:2335-2346. doi: 10.2147/NDT.S485884. eCollection 2024.
本文引用的文献
1
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.加拿大急性缺血性脑卒中静脉内替奈普酶与阿替普酶比较（AcT）：一项实用的、多中心、开放标签、与登记系统相关联、随机化、对照、非劣效性试验。
Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29.
2
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.替奈普酶与阿替普酶用于墨尔本移动卒中单元早期治疗缺血性卒中的比较（TASTE-A）：一项2期随机开放标签试验
Lancet Neurol. 2022 Jun;21(6):520-527. doi: 10.1016/S1474-4422(22)00171-5. Epub 2022 May 4.
3
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.替奈普酶与阿替普酶治疗挪威急性缺血性卒中（NOR-TEST 2，A部分）：一项3期随机开放标签盲终点非劣效性试验
Lancet Neurol. 2022 Jun;21(6):511-519. doi: 10.1016/S1474-4422(22)00124-7. Epub 2022 May 4.
4
Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.替奈普酶治疗急性缺血性脑卒中的超说明书用药：系统评价和荟萃分析。
JAMA Netw Open. 2022 Mar 1;5(3):e224506. doi: 10.1001/jamanetworkopen.2022.4506.
5
Protection of multiple ischemic organs by controlled reperfusion.控制性再灌注对多个缺血器官的保护作用。
Brain Circ. 2021 Dec 21;7(4):241-246. doi: 10.4103/bc.bc_59_21. eCollection 2021 Oct-Dec.
6
Timing is everything: Exercise therapy and remote ischemic conditioning for acute ischemic stroke patients.时机至关重要：急性缺血性中风患者的运动疗法和远程缺血预处理
Brain Circ. 2021 Aug 27;7(3):178-186. doi: 10.4103/bc.bc_35_21. eCollection 2021 Jul-Sep.
7
Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.替奈普酶治疗脑卒中患者的溶栓治疗：系统评价与荟萃分析。
Am J Emerg Med. 2021 Apr;42:31-37. doi: 10.1016/j.ajem.2020.12.026. Epub 2020 Dec 24.
8
Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.静脉注射替奈普酶剂量对大血管闭塞性缺血性脑卒中患者取栓前脑再灌注的影响：EXTEND-IA TNK 第 2 部分随机临床试验。
JAMA. 2020 Apr 7;323(13):1257-1265. doi: 10.1001/jama.2020.1511.
9
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.急性缺血性脑卒中患者早期管理指南：2018 年急性缺血性脑卒中早期管理指南的更新：美国心脏协会/美国卒中协会发布的医疗保健专业人员指南。
Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
10
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.替奈普酶与阿替普酶治疗急性缺血性脑卒中的比较（NOR-TEST）：一项 3 期、随机、开放标签、盲终点试验。
Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2.
Zotero 插件